Multiple Myeloma

New myeloma treatment options show promise

(HealthDay)—New multiple myeloma treatment options appear promising for patients aged 65 years and younger and for newly diagnosed patients who are ineligible for stem-cell transplantation, according to ...

Sep 04, 2014
popularity 4 / 5 (4) | comments 0

Multiple myeloma (from Greek myelo-, bone marrow), also known as plasma cell myeloma or Kahler's disease (after Otto Kahler), is a cancer of plasma cells, a type of white blood cell normally responsible for the production of antibodies. Collections of abnormal cells accumulate in bones, where they cause bone lesions (abnormal areas of tissue), and in the bone marrow where they interfere with the production of normal blood cells. Most cases of myeloma also feature the production of a paraprotein, an abnormal antibody that can cause kidney problems and interferes with the production of normal antibodies leading to immunodeficiency. Hypercalcemia (high calcium levels) is often encountered.

Myeloma is diagnosed with blood tests (protein electrophoresis, peripheral blood smear), microscopic examination of the bone marrow (bone marrow biopsy), and radiographs of commonly involved bones. Myeloma is generally thought to be incurable, but remissions may be induced with steroids, chemotherapy, thalidomide and stem cell transplants. Newer drugs, such as lenalidomide and bortezomib, are often used in more advanced disease. Radiation therapy is sometimes used to treat bone lesions that are causing symptoms.

The disease develops in 1–4 per 100,000 people per year. It is more common in men, and for yet unknown reasons is twice as common in African Americans as it is in white Americans. With conventional treatment, the prognosis is 3–4 years, which may be extended to 5–7 years or longer with advanced treatments. Multiple myeloma is the least common hematological malignancy (14%) and constitutes 1% of all cancers.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Berberine compound may play role in treating obesity

(Medical Xpress)—Weight-gain warnings are especially uncomfortable during holiday seasons with all the oversized and double helpings of calorie-rich pies, creamy dips and savory holiday stuffings. Nonetheless, ...

Some people may be pre-wired to be bilingual

(HealthDay)—Some people's brains seem pre-wired to acquire a second language, new research suggests. But anyone who tries to move beyond their mother tongue will likely gain a brain boost, the small study ...

Ebola vaccine promising in first human trials

Researchers say they're a step closer to developing an Ebola vaccine, with a Phase 1 trial showing promising results, but it will be months at the earliest before it can be used in the field.

Team finds an off switch for pain

In research published in the medical journal Brain, Saint Louis University researcher Daniela Salvemini, Ph.D. and colleagues within SLU, the National Institutes of Health (NIH) and other academic institutions have d ...

Vaccines may make war on cancer personal

In the near future, physicians may treat some cancer patients with personalized vaccines that spur their immune systems to attack malignant tumors. New research led by scientists at Washington University ...